Clinical Trial Update: Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating ruxolitinib in combination with venetoclax with and without azacitidine for relapsed or refractory acute myeloid leukemia is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Ruxolitinib (ruxolitinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Jennifer Saultz | Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING